Interferon-α neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-αn3

Human Antibodies

Volumn 8, Issue 3, 1997, Pages 129-136

  Zhao, Xiao Xia ^a   Hua, Ji ^a   Smith, Teresa ^a   Ferencz Biro, Katalin ^a   Liao, Mei June ^a   Rashidbaigi, Abbas ^a,b  

^a Interferon Sciences   (United States)

^b Interferon Sciences Inc   (United States)

Author keywords

Antibody; HCV; HIV; Human; Interferon; Leukocyte; Neutralizing

Indexed keywords

ALPHA INTERFERON; ALPHAN3 INTERFERON; NEUTRALIZING ANTIBODY; RECOMBINANT ALPHA2B INTERFERON;

ARTICLE; CLINICAL TRIAL; CROSS REACTION; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030823332     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/hab-1997-8304     Document Type: Article

References (50)

1. Lane HC, Kovacs JA, Feinberg J, Herpin B, Davey V, Walker R, Deyton L, Metcalf JA, Baseler M, Salzman N, et al. Anti-retroviral effects of interferon-α in AIDS-associated Kaposi's sarcoma. Lancet 1988; II: 1218
2. Friedman-Kien AE, Eron LJ, Conant M, Growdon W, Radiak H, Bradstreet PW, Fedorczyk D, Trout JR, Plasse T. Natural interferon alfa for treatment of condyloma acuminata. JAMA 1988; 259: 533
3. Bellati G, Pedraglio E, Leandro G, Ideo G. Therapy of nonA nonB (C) chronic hepatitis with recombinant α2a interferon or lymphoblastoid interferon. A randomized, controlled clinical trial final report. J Interferon Res 1991; 11: S247.4
4. Jones GJ, Itti LM. Safety and tolerance of recombinant interferon alpha-2a (Roferon A) in cancer patients. Cancer 1986; 57: 1709
5. Pastore G, Santantonio T, Milella M, et al. Changes of HBV markers in serum and liver tissue in patients with chronic hepatitis B treated with recombinant alpha-interferon (rIFN): Results of a controlled study. Antiviral Chem Chemother 1990; 1: 329
6. Carreno V, Porres JC, Mora I, Bartolome J, Bas, C Gutiez J, Cortes J, Hernandez Guio C. Prolonged (6 months) treatment of chronic hepatitis B virus infection with recombinant leukocyte A interferon. Liver 1987; 7: 325
7. Davies GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr., Perrilo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, et al. Treatment of chronic hepatitis C with recombinant interferon. A multicenter, randomized, controlled trial. N Engl J Med 1989; 32: 1501
8. Hess G. Treatment of chronic hepatitis C. Hepatology 1991; 13: S17
9. Liao MJ, Axelrod HR, Kuchler M, Yip Y-K, Kirkbright E, Testa D. Absence of neutralizing antibodies to interferon in Condyloma acuminata and cancer patients treated with natural human leukocyte interferon. J Infectious Dis 1992; 165: 757
10. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemmonier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput, JC, and the Multicenter Study Group. A comparison of three interferon Alfa-2b regimens for the long term treatment of chronic NonA, NonB hepatitis. N Engl J Med 1995; 332: 1457
11. Von Wussow P, Jakschies D, Freund M, Hehlmann R, Brockhause F, Hockeppel H, Horisberger M, Deicher H. Treatment of anti-rIFNα antibody positive CML patients with natural IFNα. Br J Haematol 1991; 78: 210
12. Portes JC, Carreno V, Ruiz M, Marron JA, Bartolome J. Interferon antibodies in patients with chronic HBV infection treated with recombinant Interferon. J Hepatol 1989; 8: 351
13. Hennes U, Jucker W, Fischer EA, Krummenacher T, Palleroni AV, Trown PW, Linder-Ciccolunghi S, Rainisi M. The detection of antibodies to recombinant interferon Alfa-2a in human serum. J Biol Standard 1987; 15: 231
14. Itri LM, Sherman MI, Palleroni AV, Evans LM Tran LL, Campion M, Chizzonite R. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-α2a. J Interferon Res 1989; 9: S9
15. Steis RG, Smith JEW, Urba WJ 2d, Urban WJ, Venzon DJ, Longo D, Barney R, Evans LM, Itri LM, Ewel CH. Resistance to recombinant interferon alfa-2a in hairy-cell leukaemia associated with neutralizing interferon antibodies. N Engl J Med 1988; 318: 1409
16. Rumi MG, del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, Zahm F, Colombo M. Long-term titrated recombinant interferon-alpha 2a in chronic hepatitis C: A randomized controlled trial. J Viral Hepatitis 1995; 2: 73
17. Lok AS, Lai CL, Leung E. Interferon antibodies may negate the antiviral effects of recombination α-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 1990; 12: 1266
18. Roffi L, Mels GC, Antonelli G, Bellati G, Panizzuti F, Piperno A, Pozzi M, Ravizza D, Angeli G, Dianzani F, et al. Breakthrough during recombination interferon alfa therapy in patients with chronic hepatitis C virus infection: Prevalence, aetiology, and management. Hepatology 1995; 21: 645
19. Oberg K, Alm G, Magnuson A, Lundqvist G, Theordorsson E, Wilander E. Treatment of malignant carcinoid tumors with recombinant interferon alpha-2b: Development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989; 81: 531
20. Von Wussow P, Hartmann F, Freund M, Poliwoda H, Deicher H. Leukocyte-derived interferon-α in patients with antibodies to rIFN-α2b. Lancet 1988; I: 882
21. Weck PK, Leventhal BG, Brand C, Finter NB. Detection and incidence of neutralizing antibodies to IFN-αn1. J Interferon Res 1989; 9: S37
22. Dianzani F. Biological basis for the Clincial use of interferon. Gut 1993; 34: S74
23. Borden E, Finte E, Friedman R, Green I, Green J, Grossberg S, Hoofnagle J, Itri L, Kawada Y, Kramer S, Laughlin C, Palleroni A, Reichman R, Steis R, Teitelbaum A, Thrumond L, Treuhaft M, Trown P, Vilcek I, von Wussow P, Zoon K. Human antibodies to interferons: Report of a National Institute of Health workshop. 25-26 July 1988 Bethesda, MD. J Interferon Res 1988; 8: v
24. Von Wussow P, Pralle H, Hochkeppel HK, Jakschies D, Sonnen S, Schmidt H, Muller-Rosenau D, Rranke M, Haferlach T, Zwingers T, et al. Effective natural IFN-α therapy in recombinant IFN-α resistant patients with hairy cell leukaemia. Blood 1991; 78: 38
25. Antonelli G, Giannelli G, Pistello M, Maggi F, Vatteroni L, Currenti M, Del Vecchio S, Roffi L, Pastore G, Dianzani F. Clinical significance of recombinant interferon α2 neutralizing antibodies in hepatitis patients. J Interferon Res 1994; 14: 211
26. Milella M, Antonelli G, Santantoion T, Giannelli G, Currenti M, Monno L, Turriziani O, Pastore G, Dianzani F. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. Hepato-Gastroenterology 1995; 42: 201
27. Skillman D, Malone JL, Decker CF, Wagner KF, Mapou RL, Liao M-J, Testa D, Meltzer MS. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: Evidence for drug safety, tolerance, and antiviral activity. J Infectious Dis 1996; 173: 1107
28. Simon DM, Gordon SC, Kaplan MM, Koff R, Regenstein F, Everson G, Lee Y, Weiner F, Silverman A, Plasse T, Fedorczyk D, Liao M-J. Treatment of chronic hepatitis C with interferon alfa-n3: A multicenter, randomized, open label trial. Hepatology 1997; 25: 445
29. Testa D, Liao M-J, Ferencz-Biro K, Rashidbaigi A, DiPaola M, Padhye M. Alpha interferon composition and method for its production from human peripheral blood leukocytes. U S Pat No. 5,503,828: April 2, 1996
30. Horowitz B. Large scale production and recovery of human leukocyte interferon from peripheral blood leukocytes. Methods Enzymol 1986; 119: 39
31. Cantell K Hirvonen S. Preparation and assay of Sendai virus. Methods Enzymol 1981; 78: 299
32. Familletti PC, Rubinstein S, Pestka S. A convenient and rapid cytopathic effect inhibition assay for interferon. Methods Enzymol 1981; 78: 387
33. Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol 1986; 119: 558
34. DiPaola M, Smith T, Ferencz-Biro K, Leao M-J Testa D. Interferon-α2 produced by normal human leukocytes is predominantly interferon-α2b. J Interferon Res 1994; 14: 325
35. Edman P, Begg G. A protein sequenator. Eur J Biochem 1967; 1: 80
36. Simon DM, Gordon SC, Kaplan MM, et al. Natural alfa interferon (Alferon® N) treatment of chronic hepatitis C in previously untreated patients. Hepatology 1995; 22: 151A
37. Gordon SC, Everson G, McHutchison JG, Reinus J, Regenstein F, Kaplan MM, Koff RS, Fedorczyk D, Plasse T. Natural alfa interferon (Alferon® N) treatment of chronic hepatitis C in patients refractory to recombinant interferon alfa 2b. Hepatology 1995; 22: 117A
38. Von Wussow P, Hehlmann R, Hochhaus T, Jakschies D, Nolte U, Prummer O, Ansari H, Hasford J, Heimpel H, Deicher H. Roferon (rIFN-α2a) is more immunogenic than Intron A (rIFN-α2b) in patients with chronic myelogenous leukaemia. J Interferon Res 1994; 14: 217
39. Antonelli G, Currenti M, Tumziani O, Dianzani F. Neutralizing antibodies to interferon-alpha: Relative frequency in patients treated with different interferon preparations. J Infect Dis 1991; 163: 882
40. Milella M, Antonelli M, Santantonio T, Currenti M, Monno L, Mariano M, Angarano G, Dianzani F, Pastore G, Dianzani F. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver 1993; 13: 146
41. Viscomi GC, Grimaldi M, Palazzini E, Silvestri S., Human leukocyte interferon alpha: Pharmacology, and therapeutic applications. Medicina Res Rev 1995; 15: 445
42. Liao M-J, Lee N, DiPaola M, Hussain M, Brissette R, Ni D, Smith T, Desai M, Ferencz-Biro K, Testa D. Distribution of interferon-α2b genes in human. J Interferon Res 1994; 14: 183
43. Lee N, Ni D, Brissette R, Chou M, Hussain M, Gill DS, Liao M-J, Testa D. Interferon-α2 variants in the human genome. J Interferon Cytokine Res 1995; 15: 341
44. Nolte KU, Raida M, Gunther G, Von Wussow P. Presence of oligomers and high molecular weight aggregates in Roferon and Intron A. J Interferon Cytokine Res 1995; 15: S218
45. Thurmond L, Chapman S, Buckley S, Wold D. Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-N1: Papilloma Study Group. New Engl J Med 1991; 325: 613
46. Thrumond LM, Brand CM, Leventhal BG, Finter NB, Johnston JM. Antibody in patients with recurrent respiratory papillomatosis treated with lymphoblastoid interferon. J Lab Clin Med 1991; 118: 232
47. Fierlbeck G, Schreiner T, Rassner G. Combination of highly purified human leukocyte interferon alpha and 13-cis-retinoic acid for the treatment of metastatic melanoma. Cancer Immunol Immunother 1995; 40: 157
48. Casato M, Antonelli G, Maggi F, Pucillo LP, Di Lullo L, Leoni M, Currenti M, Dianzani F, Bonomo L. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: Reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients. J Biol Reg Homeopathic Agents 1994; 8: 56
49. Nolte KU, Jakschies D, Pestka S, Von Wussow P. Different specificities of SLE-derived and therapy induced interferon-α2 antibodies. J Interferon Res 1994; 14: 197
50. Brand CM, Leadbeater L, Bellati G, Marotta F, Ideo G. Antibodies developing against a single recombinant interferon prolein may neutralize other IFN-α subtypes. J Interferon Res 1993; 13: 121